| Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non–small cell lung cancer with use of a next-generation sequencing … Z Wang, J Duan, S Cai, M Han, H Dong, J Zhao, B Zhu, S Wang, M Zhuo, ... JAMA oncology 5 (5), 696-702, 2019 | 432 | 2019 |
| Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis J Duan, L Cui, X Zhao, H Bai, S Cai, G Wang, Z Zhao, J Zhao, S Chen, ... JAMA oncology 6 (3), 375-384, 2020 | 260 | 2020 |
| Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade Z Wang, J Zhao, G Wang, F Zhang, Z Zhang, F Zhang, Y Zhang, H Dong, ... Cancer Research 78 (22), 6486-6496, 2018 | 200 | 2018 |
| Deactivation of excitatory neurons in the prelimbic cortex via Cdk5 promotes pain sensation and anxiety GQ Wang, C Cen, C Li, S Cao, N Wang, Z Zhou, XM Liu, Y Xu, NX Tian, ... Nature communications 6 (1), 1-16, 2015 | 189 | 2015 |
| Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+ IPI: a systematic review and meta-analysis P Xing, F Zhang, G Wang, Y Xu, C Li, S Wang, Y Guo, S Cai, Y Wang, J Li Journal for immunotherapy of cancer 7 (1), 1-10, 2019 | 154 | 2019 |
| Pretreatment lactate dehydrogenase may predict outcome of advanced non small‐cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis Z Zhang, Y Li, X Yan, Q Song, G Wang, Y Hu, S Jiao, J Wang Cancer medicine 8 (4), 1467-1473, 2019 | 124 | 2019 |
| Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial X Chen, X Wu, H Wu, Y Gu, Y Shao, Q Shao, F Zhu, X Li, X Qian, J Hu, ... Journal for immunotherapy of cancer 8 (2), 2020 | 110 | 2020 |
| Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study P Cui, Z Liu, G Wang, J Ma, Y Qian, F Zhang, C Han, Y Long, Y Li, ... Cancer Medicine 7 (8), 4115-4120, 2018 | 95 | 2018 |
| Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLCNOTCH Mutation and Efficacious Immunotherapy in NSCLC K Zhang, X Hong, Z Song, Y Xu, C Li, G Wang, Y Zhang, X Zhao, Z Zhao, ... Clinical Cancer Research 26 (14), 3649-3661, 2020 | 88 | 2020 |
| Circulating cell-free DNA for cancer early detection Q Gao, Q Zeng, Z Wang, C Li, Y Xu, P Cui, X Zhu, H Lu, G Wang, S Cai, ... The Innovation 3 (4), 2022 | 79 | 2022 |
| Efficacy and safety of first-line immunotherapy combinations for advanced NSCLC: a systematic review and network meta-analysis L Liu, H Bai, C Wang, S Seery, Z Wang, J Duan, S Li, P Xue, G Wang, ... Journal of Thoracic Oncology 16 (7), 1099-1117, 2021 | 76 | 2021 |
| Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L) 1 Inhibitors Z Wang, J Duan, G Wang, J Zhao, J Xu, J Han, Z Zhao, J Zhao, B Zhu, ... Journal of Thoracic Oncology 15 (4), 556-567, 2020 | 72 | 2020 |
| Pretreatment neutrophil-to-lymphocyte ratio (NLR) may predict the outcomes of advanced non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) Y Li, Z Zhang, Y Hu, X Yan, Q Song, G Wang, R Chen, S Jiao, J Wang Frontiers in Oncology 10, 654, 2020 | 68 | 2020 |
| A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B T Yang, H Xing, G Wang, N Wang, M Liu, C Yan, H Li, L Wei, S Li, Z Fan, ... Clinical chemistry 65 (12), 1543-1553, 2019 | 63 | 2019 |
| TP53 mutation as potential negative predictor for response of anti-CTLA-4 therapy in metastatic melanoma W Xiao, N Du, T Huang, J Guo, X Mo, T Yuan, Y Chen, T Ye, C Xu, ... EBioMedicine 32, 119-124, 2018 | 55 | 2018 |
| Efficacy, acceptability and tolerability of 8 atypical antipsychotics in Chinese patients with acute schizophrenia: a network meta-analysis Z Bai, G Wang, S Cai, X Ding, W Liu, D Huang, W Shen, J Zhang, K Chen, ... Schizophrenia Research 185, 73-79, 2017 | 31 | 2017 |
| Co-occurring genomic alterations and immunotherapy efficacy in NSCLC F Zhang, J Wang, Y Xu, S Cai, T Li, G Wang, C Li, L Zhao, Y Hu NPJ precision oncology 6 (1), 1-12, 2022 | 28 | 2022 |
| Association between DNA damage repair gene somatic mutations and immune‐related gene expression in ovarian cancer W Tian, B Shan, Y Zhang, Y Ren, S Liang, J Zhao, Z Zhao, G Wang, ... Cancer medicine 9 (6), 2190-2200, 2020 | 28 | 2020 |
| EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma H Bai, J Duan, C Li, W Xie, W Fang, Y Xu, G Wang, R Wan, J Sun, J Xu, ... Journal for immunotherapy of cancer 8 (2), 2020 | 28 | 2020 |
| The tumor mutational burden of Chinese advanced cancer patients estimated by a 381-cancer-gene panel WU Zhuang, J Ma, X Chen, G Wang, J Lu, Y Chen, H Dong, S Cai, ... Journal of Cancer 9 (13), 2302, 2018 | 26 | 2018 |
